Bogdan Knezevic’s Post

View profile for Bogdan Knezevic, graphic

Scientist | Technologist | Co-founder & CEO @ Kaleidoscope.bio

Last week was my first time attending the Yale Ventures Innovation Summit, which was a really cool way to see the CT ecosystem come together. I wasn't aware of the breadth of work coming out of this network (thanks Erika Smith for letting me know about it!). Seeing so many people from bio, materials, climate, health, and humanities come together made for some really interesting conversation (and not something I'm used to experiencing at very bio-heavy conferences). One of the talks I really enjoyed was Matt Truppo's discussion around the work Sanofi (and others) are doing when it comes to leveraging digital advances across the drug R&D process. He encouraged the field to think about advances in a more step-wise way -- taking something down from a few weeks of work to a few hours is a big deal, even if you haven't fully automated your process. You don't need to make binary leaps ('manual process' vs 'AI process') to reap big, compounding gains. Listening to the biotech company pitches also made it clear that now, more than ever, there's a need for running a focused pipeline, with a clear plan of what assets you're prioritizing, what data you're generating, and what experiments you need to be running. For those interested, we recently published a piece on why this is so critical in biotech: https://lnkd.in/eTSEKBpE

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics